9989:HKEXShenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Analysis

The moving-average structure behind Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is neutral at HKD 4.30, with no clear ordering between short and long averages. Momentum indicators put RSI at 48.2 (neutral) with MACD reading bearish. The recent range runs from support at HKD 4.14 up to resistance at HKD 4.68.
Valuation screens as undervalued: a P/E of 26.9 sits below the sector average of 30.4. Consensus targets land 4.8% below where the shares trade now. Revenue is contracting at 12.3% on a 3.9% profit margin. The 3.84% dividend yield looks stretched against payout coverage.
Risk scores 7 out of 10, which is elevated for this asset class. With 30-day volatility of 39.1%, a beta of 0.31 and a maximum drawdown of 38.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.